Commercialization of Regenerative Medicine: Learning from Spin-Outs

By admin

Tweet The meeting “Commercialization of Your Regenerative Medicine Research: Lessons from Spin Out Successes” was hosted by the Oxbridge Biotech Roundtable (OBR) (Oxford, UK) at the University of Oxford in February, 2013, and attracted a multi-stakeholder audience spanning academia and industry. The event featured case studies from Gregg Sando, CEO, Cell Medica (London, UK), John Sinden, CSO, […]

Regenerative MedicineComments Off on Commercialization of Regenerative Medicine: Learning from Spin-Outs | April 28th, 2013

2013 Annual Regenerative Medicine Industry Report

By admin

Tweet The Alliance for Regenerative Medicine announced today the release of the 2013 annual regenerative medicine industry report. Here is the announcement in the Wall Street Journal online.I’m proud to have been a part of putting it together and hope people find it useful. It is available for download on the ARM website here. In addition […]

Cell Therapy Blog welcomes 2013

By admin

Tweet Happy new year to all our readers. We look forward to our interactions throughout 2013. This month watch for:a post summarizing some of the things we think are watch-worthy in the cell therapy industry in 2013, our recap of the money cell therapy and cell-based regenerative medicine companies raised in 2012, andus to formalize our position statement on […]

The Accuracy of Adipose Stem Cell Doses

By admin

Tweet In August we published a blog post, “Are some cell counts too good to be true? Why some companies’ product data may mislead“, pointing people to a white paper released by INCELL Corporation. That white paper appears now to have been pulled from their website (we are working to get a copy to make available again) […]

The ROI on pant-wearing and other social media tips

By admin

Tweet With many things in life, there is a payoff for doing them. Do the dishes and the kitchen is cleaner, your household is more functional, and hopefully one or more family members notice and appreciate you for it.For other things, however, the people around you have such high expectations you’ll do them that you only […]

By admin

Tweet Further to my recent post, “Six steps to fighting non-compliant cell therapy treatments. The stuff of grey shades, spades, ivory towers and (ahem) balls.“, I have crafted a 6-point platform that I propose to submit (with potential edits based on preliminary feedback) to several of the leading industry and professional organizations for their consideration including ARM, […]

By admin

Tweet Today an article entitled “Professors Critique Stem Cell Medical Tourism” appeared in the online version of The Harvard Crimson summarizing a recent panel discussion hosted in least in part by Harvard Law School assistant professor I. Glenn Cohen and University of Alberta law professor Timothy Caulfield. The article concludes thusly:The panelists emphasized that more accurate information should […]

Cell Therapy Industry Group Welcomes its 4,000th member

By admin

Tweet I’m pleased to point out that today the LinkedIn Cell Therapy Industry Group welcomed its 4,000th member today. The Cell Therapy Industry group was created to serve as a network of those in the cell therapy industry. The group acts as a vehicle for referrals, networking, information, and facilitating collaboration. The group’s focus is on the activities of […]

By admin

Tweet We first provided a listing (with very few details) of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials on this blog late last year (see the posting here).We are now pleased to we have worked with Genetic Engineering and Biotechnology News and Enal Razvi of Select Biosciences to provide an updated (as of June 2012) and […]

CIRM addresses some tough questions. Is it all just glass towers and basic research?

By admin

Tweet At an industry conference recently I heard several new grumbles from companies about CIRM’s alleged heavy bias toward funding basic, pre-clinical, embryonic stem cell-focused, academic-based research over clinical-stage, adult stem cell-focused, industry-sponsored product trials, testing, and development.I myself have shared some concern that for an agency with a key goal of bringing new medicines to the […]

Regenerative MedicineComments Off on CIRM addresses some tough questions. Is it all just glass towers and basic research? | October 21st, 2012

Cell therapy portfolio outperforms major indices year-to-date

By admin

Tweet On August 10 we created a model portfolio in Google Finance of 29 public companies in the cell therapy sector then we compared how that portfolio was doing against the major indices year-to-date (Since 1 January 2012). See that post here. Bottom line: even though we are still in a relatively bullish market, the CT portfolio was […]

The cost of clinical trial data bias/loss, FDA’s new job and the need for bold leadership.

By admin

Tweet The scandal of clinical trial data loss is eroding the fundamentals of evidence-based research and clinical medicine.Before you right this post off as the stuff of conspiracy theories, fear-mongering, and ‘alternative world views’ consider that this view is shared by the likes of the FDA, the International Committee of Medical Journal Editors, the Cochrane Collaboration, […]

Regenerative MedicineComments Off on The cost of clinical trial data bias/loss, FDA’s new job and the need for bold leadership. | September 30th, 2012

Anticipated short-term cell therapy industry clinical milestones

By admin

Tweet What follows is an interesting but not exhaustive list of cell therapy industry clinical milestones we anticipate in the next 3-9 months as selected from the list of cell therapy products we are tracking in late-stage or post-commercial development. There are other commercial milestones we are monitoring as well as other clinical milestones we expect […]

Two lessons I learned this week.

By admin

Tweet I learned two valuable things this week I thought I’d pass on in a Friday afternoon post. Actually strictly speaking these are likely things I’ve learned before but needed to re-learn or to be ‘reminded’ of their importance.Please pardon a little stroll away from the typically strict focus on cell therapy — but in a […]

Are some cell counts too good to be true? Why some companies’ product data may mislead.

By admin

Tweet This is a cautionary tale about the need for robust product characterization and release specifications for all cell therapy products.BackgroundWhile our food often has a list of ingredients, our drugs don’t. We rely on our regulatory agencies to rule on the safety of our drugs. These agencies require drug manufacturers to submit to them the […]

Regenerative MedicineComments Off on Are some cell counts too good to be true? Why some companies’ product data may mislead. | September 2nd, 2012

Is the cell therapy sector outperforming the major indices?

By admin

Tweet So here’s what I did today. I built a portfolio of public companies focused exclusively or predominately in the cell therapy space. I excluded any companies that are in the sector but their products/services constitute less than a significant majority of their revenue and/or expenses. The portfolio sits at 29 companies. Here’s the list:Here’s how […]

Regenerative MedicineComments Off on Is the cell therapy sector outperforming the major indices? | August 12th, 2012

FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012)

By admin

Tweet As followers of this blog will know I’ve been blogging about Regenerative Sciences and predicting their eventual run-in with the FDA since my first post in September 2008 (Cell Therapy is Not the Practice of Medicine) and again in February 2009 (Regenexx vs the FDA 2009). When the FDA finally proceeded with an injunction against […]

By admin

TweetA short and sweet note to point you to a great article on bioreactor technologies related to cell therapy bioprocessing by CTG consultant and Director of Stem Cell-based Drug Discovery, John E. Hambor, who you can now follow on Twitter @StemCellonDrugs.“Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing” was published in the June issue […]

Industry-sponsored cardiovascular cell therapies. Some metrics.

By admin

TweetCell therapies for cardiovascular-related conditions is a closely watched, much studied, oft-discussed, and hotly contested segment of the cell therapy industry.The data to-date are admittedly confusing. From a clinical perspective, the studies for which we have data have been relatively small involving a mish-mash of indications, endpoints, eligibility criterion, methods and/or route of administration, as […]

Cell-based Cancer Immunotherapies. Some metrics..

By admin

Tweet Whatever one makes of Dendreon‘s challenges in bringing Provenge to market and then its ups and downs in the market, the whole affair has brought a much bigger spotlight to cancer immunotherapies and cell-based immunotherapies in particular.This is true on all fronts. Cancer immunotherapy conferences are popping up everywhere. A growing number of of analysts […]